Financial Performance - The company's revenue for Q1 2023 reached ¥6,352,408,318.71, representing a 49.46% increase compared to ¥4,194,386,685.74 in the same period last year[4] - Net profit attributable to shareholders was ¥1,151,030,150.88, up 36.90% from ¥838,713,628.38 year-on-year[4] - The net profit excluding non-recurring gains and losses was ¥1,131,213,788.87, reflecting a 41.86% increase from ¥797,413,610.83 in the previous year[4] - Revenue for Q1 2023 reached CNY 6,352,408,318.71, a 49.46% increase compared to CNY 4,250,226,596.43 in the same period last year[10] - Total operating revenue for Q1 2023 reached CNY 6,352,408,318.71, a significant increase of 49.5% compared to CNY 4,250,226,596.43 in Q1 2022[21] - Net profit for Q1 2023 was CNY 1,229,459,986.52, representing a year-over-year growth of 44.7% from CNY 849,604,681.09 in Q1 2022[21] - Operating profit increased to CNY 1,513,898,999.37, up 47.4% from CNY 1,026,677,610.57 in the same period last year[21] Cash Flow and Assets - The company's cash flow from operating activities decreased by 32.99% to ¥301,166,852.20, down from ¥459,140,529.66 in the same quarter last year[4] - Net cash flow from operating activities decreased by 32.99% to CNY 301,166,852.20, down from CNY 449,424,955.24 in the previous year[10] - Cash inflow from operating activities totaled CNY 6,156,670,173.57, up from CNY 4,276,978,435.80 in Q1 2022[23] - Total assets at the end of the reporting period were ¥37,879,854,016.08, a 39.66% increase from ¥27,122,781,699.16 at the end of the previous year[5] - Total assets increased to CNY 37,879,854,016.08, compared to CNY 27,122,781,699.16 at the end of Q1 2022, reflecting a growth of 39.5%[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 28,162[13] - The largest shareholder, China Resources Pharmaceutical Group, holds 62.99% of the shares[13] - The company has not disclosed any related party transactions among its top shareholders, ensuring transparency in its shareholder structure[14] Investments and Acquisitions - The company completed the acquisition of control over Kunming Pharmaceutical Group Co., Ltd., which significantly impacted its financial metrics[9] - The company completed the acquisition of a 28% stake in Kunming Pharmaceutical Group Co., Ltd. for a total transaction price of RMB 2.902 billion, with a per-share transfer price of RMB 13.67[15] - The company is focused on expanding its market presence and enhancing its product portfolio through strategic acquisitions and investments in R&D[15] - The company plans to continue expanding its market presence and investing in new technologies and products[10] Liabilities and Equity - Total liabilities rose to CNY 14,728,791,237.19, up from CNY 9,589,366,999.99, marking a 53.5% increase year-over-year[20] - Shareholders' equity attributable to the company increased by 6.87% to ¥18,177,577,940.58 from ¥17,009,633,485.53 at the end of the last year[5] - The company's equity attributable to shareholders reached CNY 18,177,577,940.58, an increase from CNY 17,009,633,485.53 in Q1 2022[20] Research and Development - Research and development expenses rose to CNY 132,597,016.85, an increase of 27.3% compared to CNY 104,151,173.24 in Q1 2022[21] Inventory and Receivables - Accounts receivable increased by 67.77% to ¥6,857,416,276.69 from ¥4,087,323,874.81 year-on-year[9] - Inventory grew by 73.56% to ¥4,337,017,034.56 from ¥2,498,868,530.92 in the same period last year[9] - Accounts receivable rose to RMB 6.86 billion, compared to RMB 4.09 billion at the beginning of the year, marking an increase of approximately 67.5%[19] - Inventory levels increased to RMB 4.34 billion from RMB 2.50 billion, indicating a growth of around 73.5%[19] Cash and Cash Equivalents - Cash and cash equivalents rose by 69.23% to ¥5,330,115,565.97 compared to ¥3,149,708,926.94 in the previous year[9] - Cash and cash equivalents increased to RMB 5.33 billion from RMB 3.15 billion, reflecting a growth of about 69.5%[19] - The ending balance of cash and cash equivalents reached ¥4,436,059,607.81, an increase from ¥2,774,870,713.46 at the end of Q1 2022[25]

华润三九 2022年度业绩说明会 华润三九医药股份有限公司 二O二三年四月 目 录 业绩回顾 业务举措 未来展望 2 Part 1 2022年业绩回顾 业绩回顾 2022年业绩表现 营业收入 180.79亿元 同比增长 +16.31% 139.65 2020 2021 2022 155.44 180.79 同比增长 2022 归母净利润 24.49亿元 +19.16% 16.04 2020 2021 20.55 24.49 经营活动产生的现 金流量净额 30.06亿元 同比增长 +59.52% 22.38 2020 2021 2022 18.85 30.06 归母净利润（扣非） 22.19亿元 同比增长 +19.75% 13.35 2020 2021 2022 18.53 22.19 4 业绩回顾 2022年收入结构 ● 制药业务 96.02% ● 非制药业务 3.98% 173.60亿，增长16.90% ● CHC健康消费品 62.97% 113.84亿，增长22.73% ● 处方药 33.05% 59.76亿，增长7.19% ● 总营业额 180.79亿，增长16.31% 5 创新发展 质量管理 绿色发展 ...

华润三九医药股份有限公司 关于举行 2022 年度业绩说明会的公告 证券代码：000999 证券简称：华润三九 公告编号：2023-015 （一） 会议召开时间： 2023 年 4 月 7 日下午 15:30-16:30 （二） 网络直播地址： 全景路演（https://rs.p5w.net） （三） 会议召开方式： 现场交流、网络直播 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 华润三九医药股份有限公司(以下简称"公司")于 2023 年 3 月 29 日发布公司 2022 年年度报告，为便于投资者了解公司 2022 年度生产经营情况及未来发展规划，公司将 于 2023 年 4 月 7 日（星期五）下午 15:30-16:30 举办 2022 年度业绩说明会。 一、业绩说明会召开的时间、地点 二、参加人员 公司董事长邱华伟先生，董事、总裁赵炳祥先生，董事、副总裁兼董事会秘书周辉 女士，财务总监梁征先生，副总裁王亮先生将出席公司 2022 年度业绩说明会。 三、投资者参加方式 1. 投资者可于 2023 年 4 月 7 日（星期五）下午 15:30-16: ...

Financial Performance - The company's operating revenue for 2022 was ¥18,079,461,482.75, representing a 16.31% increase compared to ¥15,544,401,735.35 in 2021[17]. - The net profit attributable to shareholders for 2022 was ¥2,448,802,103.34, which is a 19.16% increase from ¥2,055,104,407.14 in 2021[17]. - The net profit after deducting non-recurring gains and losses was ¥2,218,917,217.36, up 19.75% from ¥1,852,916,806.59 in the previous year[17]. - The net cash flow from operating activities reached ¥3,006,375,016.25, marking a significant increase of 59.52% compared to ¥1,884,653,344.33 in 2021[17]. - The total assets at the end of 2022 were ¥27,122,781,699.16, reflecting a 10.52% increase from ¥24,541,900,747.88 at the end of 2021[18]. - The net assets attributable to shareholders increased to ¥17,009,633,485.53, an 11.08% rise from ¥15,313,186,861.46 in 2021[18]. - The company reported a basic earnings per share of ¥2.48 for 2022, which is an 18.10% increase from ¥2.10 in 2021[17]. - The weighted average return on equity for 2022 was 15.15%, up from 14.14% in 2021[17]. - The total revenue for 2022 reached ¥18.08 billion, representing a 16.31% increase from ¥15.54 billion in 2021[50]. - The pharmaceutical sector contributed ¥17.36 billion, accounting for 96.02% of total revenue, with a year-on-year growth of 16.90%[51]. - The self-medication segment (CHC) generated ¥11.38 billion, which is 62.97% of total revenue, showing a 22.73% increase year-on-year[51]. - The gross profit margin for the pharmaceutical sector decreased to 55.38%, down by 5.56% compared to the previous year[51]. Market and Growth Strategy - The company plans to expand its market presence and enhance its product offerings in response to the evolving healthcare policies and industry trends[23]. - The company aims to enhance its product offerings in chronic disease management, focusing on high-value products and services to assist patients effectively[28]. - The company is actively exploring the internet healthcare market and has covered thousands of hospitals and tens of thousands of grassroots medical institutions nationwide[30]. - The company plans to optimize its channel structure and expand new channels to improve customer satisfaction and resource efficiency[30]. - The company is leveraging its brand strategy to develop specialized brands in pediatric, orthopedic, and gynecological products, enhancing its market presence[28]. - The company anticipates long-term growth opportunities in the pharmaceutical industry driven by increasing health demands and policy support for traditional Chinese medicine[75]. - The health consumer goods market is expected to expand, with a focus on self-diagnosis and diversified health solutions catering to consumer needs throughout their life cycle[76]. - The company is focusing on the chronic disease sector as a new growth driver, influenced by an aging population and rising chronic disease prevalence[76]. - The company aims to double its revenue during the 14th Five-Year Plan period and become a leading enterprise in the industry[80]. - The company plans to enhance its innovation system and increase investment in R&D, focusing on self-diagnosis and treatment for key demographics such as the elderly and children[81]. - The company will strengthen its digital capabilities and marketing strategies, particularly in the e-commerce and O2O channels, to expand its market presence[82]. Research and Development - R&D investment reached 736 million yuan, with a significant increase in the proportion of new product development[33]. - The company has 77 ongoing research projects, focusing on strategic areas such as oncology and respiratory diseases[33]. - The company introduced three new drug registration certificates, including the propofol tablet, which was selected in the seventh batch of national drug centralized procurement[34]. - The company is focusing on new product development and technological advancements as part of its growth strategy[93]. - The company is committed to improving its quality management system and promoting green development initiatives, including carbon neutrality efforts[82]. - The company will focus on the development of traditional Chinese medicine, increasing R&D efforts for classic formulas and enhancing the quality of medicinal materials[82]. - The company has over 20 classic formulas of traditional Chinese medicine under research, focusing on standardization and resource studies[135]. Risk Management - The company faces various risks including market and policy risks, R&D innovation risks, merger and integration risks, and raw material price fluctuation risks[3]. - The company emphasizes the importance of reading the full annual report and highlights potential investment risks associated with forward-looking statements[2]. - The company has implemented a robust investment management system to address risks associated with mergers and acquisitions, ensuring compliance and expected returns[88]. - The company is closely monitoring changes in medical insurance policies and adjusting its strategies accordingly to maintain competitiveness in the prescription drug market[87]. - The company has established a comprehensive R&D system and long-term planning to mitigate risks associated with new product development failures[87]. Environmental and Social Responsibility - The company has established a near-zero carbon park project at its headquarters, which includes distributed photovoltaic power generation and energy-saving renovations, and was selected as a pilot project for near-zero carbon emissions in Shenzhen by the end of 2022[175]. - The company has actively engaged in public welfare projects, including the "Health Village" initiative, which improves local healthcare environments and awareness in supported areas[181]. - The establishment of traditional Chinese medicine planting bases has effectively promoted standardized cultivation, improved rural employment, and contributed to poverty alleviation and rural revitalization[182]. - The company reported that all pollutants were discharged in compliance with national and local environmental standards, with no exceedance of approved discharge limits[170]. - The company has developed a self-monitoring plan for environmental compliance, which is submitted for regulatory approval each year[171]. Corporate Governance - The company maintained a strong governance structure, ensuring compliance with laws and regulations throughout the reporting period[96]. - The company emphasized good communication with investors, utilizing various channels such as performance communication meetings and investor relationship platforms to provide updates on development strategies and business conditions[98]. - The company operates independently from its controlling shareholder, maintaining separation in personnel, assets, finance, and operations[96]. - The company has committed to resolving and avoiding competition with its controlling shareholder, Huaren Pharmaceutical Holdings, through various measures including asset transfers and business adjustments[102]. - The company has established long-term commitments to avoid conflicts of interest and competition with Kunming Pharmaceutical Group[187]. Shareholder Engagement - The company proposed a cash dividend of 10 CNY per 10 shares, totaling 988,346,000 CNY, which represents 40.36% of the net profit attributable to shareholders[147]. - The total distributable profit for the year was 7,408,284,927.14 CNY, with the cash dividend amount accounting for 100% of the profit distribution[147]. - The company’s profit distribution plan will be submitted for approval at the annual shareholders' meeting[147]. - The company has maintained a transparent and compliant process for any adjustments to the cash dividend policy[146]. - The company provided online voting for shareholders during meetings to facilitate their rights and protect their interests[96].

众众举烟三九 CR SANJIU 97 为爱专注 为家守护 2021年度报告 ANNUAL REPORT 华润三九医药股份有限公司 2021 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人赵炳祥、主管会计工作负责人梁征及会计机构负责人(会计主管 人员)钟江声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本公司 2021 年度报告涉及的未来计划等前瞻性陈述，不构成公司对投资者 的实质承诺，请投资者注意投资风险。 本公司请投资者认真阅读本年度报告全文，并特别注意下列风险因素。公 | --- | |-----------------------------------------------------------------------------------------| | | | | | 司存在市场及政策风险、研发创新风险、并购整合风险、原材料价格波动风险 | | 等风险，敬请广大投资者注意投资风险。 ...

众公羊烟 三九 CR SANJIU 为爱专注 为家守护 半年度报告 ＩＮＴＥＲＩＭ ＲＥＰＯＲＴ 9 aluminatio 华润三九医药股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人邱华伟、主管会计工作负责人梁征及会计机构负责人(会计主管 人员)钟江声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本公司 2021 年半年度报告涉及的未来计划等前瞻性陈述，不构成公司对投 资者的实质承诺，请投资者注意投资风险。 | --- | |----------------------------------------------------------------------| | | | 本公司请投资者认真阅读本半年度报告全文，并特别注意下列风险因素。 | | 公司存在市场及政策风险、药品降价风险、原材料价格波动风险等风险，敬请 | | 广大投资者注意投资风险。详细内容见本报告 " ...